Skip to main content
. 2014 Apr 22;77(5):796–807. doi: 10.1111/bcp.12256

Figure 5.

Figure 5

Observed plasma concentration time profiles following 150 and 80 mg twice daily administration of LY2157299 and simulated pSMAD inhibition in tumour in patients. △, 150 mg twice daily; Inline graphic, 80 mg twice daily; —, 80 mg twice daily; – – –, 150 mg twice daily